An observational study in Community Acquired Pneumonia in Children and Antibiotic Stewardship, sponsored by ARCIM Institute Academic Research in Complementary and Integrative Medicine. Recruiting at 2 sites in Germany. Open to participants aged 3 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by ARCIM Institute Academic Research in Complementary and Integrative Medicine · Observational
A study to observe how often antibiotics are prescribed in children hospitalized for pneumonia and how doctors decide if a child needs antibiotics or not. Parent satisfaction will also be recorded.
An observational study to document the antibiotic treatment rate of children hospitalized for community acquired pneumonia at a pediatric department with longstanding practice of restrictive antibiotic prescribing. Patients will be enrolled consecutively and treated according to in-house standard operating procedure. Antibiotic treatment rate, severity of disease and medical complication rate in antibiotic and non-antibiotic managed children, frequency of predefined factors in physician decision making on antibiotic use, and parental satisfaction will be recorded. Parents will be contacted at least 4 weeks after discharge to inquire about recurrence or readmission.
324 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.
This study's planned enrollment of 200 is below the median of 650 across 111 observational studies indexed under Community-Acquired Pneumonia.
Browse Community-Acquired Pneumonia studies →ARCIM Institute Academic Research in Complementary and Integrative Medicine is the lead sponsor of 32 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Children (aged 3 months to 18 years) who are hospitalized for pneumonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children with non-severe community acquired pneumonia and fever: managed with antibiotics
Other: Antibiotic treatment
Children with non-severe community acquired pneumonia and fever: managed without antibiotics
Other: No antibiotic treatment
Antibiotic treatment
No antibiotic treatment
Antibiotic treatment rates in hospitalized children with non-severe community-acquired pneumonia and fever
Rates of treatment with and without antibiotics during hospitalization
Time frame: During hospitalization, an average of 7 days
Number of medical complications
Medical complications defined as a) admission to intensive care, mechanical ventilation, transfer to tertiary car center OR b) pleural effusion or empyema, pneumothorax, lung abscess, bronchopleural fistula, necrotizing pneumonia, acute respiratory failure, infectious complication (meningitis, septic shock).
Time frame: During hospitalization, an average of 7 days
Factors in physician decision making on antibiotic prescription
Physician questionnaire (closed-ended questions)
Time frame: During hospitalization, an average of 7 days
Parental satisfaction
Parental satisfaction questionnaire (closed-ended questions)
Time frame: At discharge, assessing the entire duration of the hospital stay, an average of 7 days
Hospitalization duration
Number of hospitalization days
Time frame: At discharge, assessing the entire duration of the hospital stay, an average of 7 days
Number of children with relevant comorbidity
Co-morbidities that may affect decision on antimicrobial use: a) chronic conditions (e.g. neurological conditions such as cerebral palsy, Down syndrome; or chronic respiratory conditions such as asthma, cystic fibrosis; or heart conditions). b) acute infectious comorbidities: bronchiolitis, otitis media, urinary tract infection, confirmed influenza virus or Respiratory Syncytial Virus or SARS-CoV2.
Time frame: During hospitalization, an average of 7 days
Days of supplemental oxygen use
Oxygen therapy for O2 saturation \<92%
Time frame: During hospitalization, an average of 7 days
Use of antipyretic medications
Number of doses of paracetamol or ibuprofen during hospitalization
Time frame: During hospitalization, an average of 7 days
Number of complementary medicine medications used per child
Number of complementary medication during hospitalization
Time frame: During hospitalization, an average of 7 days
Number of readmissions for pneumonia or new pneumonia recurrences within 4 weeks of hospital discharge
New hospital admission for pneumonia; treatment requiring recurrence of pneumonia
Time frame: 4 weeks after end of hospitalization
Plan to share: Yes — IPD that underlie results in a publication
Supporting information: Study protocol, Informed consent form
Time frame: The data will be made available upon publication for a duration of three months.
Access criteria: The data will be made available to researchers who provide a methodologically sound proposal for use in achieving the goals of the approved proposal.
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Dec 2027, 63 months after the start.
Of 38 observational studies under Community-Acquired Pneumonia, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's planned 63 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Community-Acquired Pneumonia →
ARCIM Institute Academic Research in Complementary and Integrative Medicine